Antiplatelet strategy in primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: A perspective from the guideline appraisal

Abstract

Aims/Introduction: To appraise guidelines on the antiplatelet strategy of prevention of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus, and highlight the consensuses and controversies to aid clinician decision-making. Materials and Methods: A systematic search was carried out for guidelines regarding CVD prevention or focusing on type 2 diabetes patients. Appraisal of Guidelines for Research and Evaluation II instrument was utilized to appraise the quality of included guidelines. Results: Of the 15 guidelines with discrepant Appraisal of Guidelines for Research and Evaluation II scores (66%; interquartile range 51-71%), 10 were defined as "strongly recommended" guidelines. For secondary prevention, >60% of guidelines advocated that the dual antiplatelet therapy was used within 12 months when the type 2 diabetes patients experienced acute coronary syndrome and/or post-percutaneous coronary intervention or coronary artery bypass grafting, with subsequent long-term aspirin use. For primary prevention, 80% of guidelines supported that aspirin should not be routinely used by patients with type 2 diabetes. No consensus on whether to prolong dual antiplatelet therapy in secondary prevention, and whether to use aspirin in type 2 diabetes patients with high CVD risk exists in current guidelines. Conclusions: Physicians should use the recommendations from "strongly recommended" guidelines to make informed decisions and know the consensuses of current guidelines. Dual antiplatelet therapy should be used within 12 months when type 2 diabetes patients experience acute coronary syndrome and/or percutaneous coronary intervention/coronary artery bypass grafting, with subsequent long-term aspirin use. In primary prevention, aspirin should not be routinely used by individuals with type 2 diabetes, but might be considered for those with high CVD risk.

Transcription Factor-7-Like-2 (TCF7L2) in Atherosclerosis: A Potential Biomarker and Therapeutic Target

“…A large sample investigation involving 584 participants revealed that compared to non-T2D participants, T2D patients suffer from more severe carotid atherosclerotic stenosis, appearing as larger lipid necrosis cores with increasing calcification ( 66 ). T2D patients are extremely susceptible to CVD, which has become the most common cause of death in T2D ( 67 ). Similar to other metabolic diseases, T2D shares several pathological factors with atherosclerosis.…”

Association of Major Adverse Cardiac Events and Beta-Blockers in Patients with and without Atherosclerotic Cardiovascular Disease: Long-Term Follow-Up Results of the T-SPARCLE and T-PPARCLE Registry in Taiwan

“…Although statistically non-significant, there was a trend of increased HR of the patients under antiplatelet therapy. This implies that many of the clinicians in Taiwan still over-used antiplatelet medication in primary-prevention patients, although recently published guidelines did not recommend routine prescription of antiplatelets for primary prevention [ 31 ].…”

Primordial Drivers of Diabetes Heart Disease: Comprehensive Insights into Insulin Resistance

“…There is no clinical study of fibrates in the treatment of T2DM complicated by HF. Antiplatelet agents help to improve islet survival and function, islet graft outcome, and insulin gene expression [117][118][119][120]. However, platelet reactivity is enhanced in patients with insulin resistance, and the risk of thrombosis and bleeding should be taken into account.…”